Development and External Validation of a Plasma p-tau217-Based Model for MCI-to-Dementia Progression
- 1University of California, San Diego
Abstract
--Clinical trajectories after a diagnosis of mild cognitive impairment (MCI) vary widely, so prognostic models must account for both the timing of subsequent diagnoses and unequal follow-up. Using the Alzheimers Disease Neuroimaging Initiative (ADNI), we developed a Cox proportional-hazards model for time from an MCI-aligned plasma index visit to a subsequent dementia diagnosis, using age at study entry and log-transformed plasma p-tau217. Coefficients and baseline survival were estimated in 401 participants with 85 events and then frozen and applied without refitting to an independent cohort from the National Alzheimers Coordinating Center (NACC). NACC p-tau217 measurements were reported on the Quanterix HD-X platform and were mapped to the ADNI development-assay scale using a prespecified transformation derived from paired ADNI measurements. The two-predictor model reached a pooled out-of-fold C-index of 0.775 in ADNI (apparent C-index, 0.778) and 0.652 (95% CI, 0.526-0.765) in 104 NACC participants with 25 incident dementia diagnoses. At two years, observed risk was 0.214 compared with a mean predicted risk of 0.089, an observed-to-expected ratio of 2.40. Neither adding APOE{varepsilon} 4 count, sex, or education nor expanding the model with GFAP, NfL, and the A{beta}42/A{beta}40 ratio materially improved discrimination in ADNI; APOE{varepsilon} 4 also provided no detectable incremental gain in NACC. The model showed moderate discrimination in NACC, although the wide confidence interval includes values near chance and the middle and higher risk tertiles did not clearly separate; C-indices were similar in the bridged primary and direct-scale sensitivity analyses, and mean two-year predicted risk was lower than observed only in the bridged analysis.
Related
- Baseline 25-hydroxyvitamin D and progression-free survival in de novo metastatic hormone-sensitive prostate cancer: prognostic model development and external validation.
- Plasma pTau217 and pTau231 predict progression to dementia in Parkinson’s disease: a prospective longitudinal study
- Development and quality evaluation of lyophilized plasma external quality assessment samples for coagulation testing in resource-limited settings
- Development and external validation of an XGBoost-based prognostic model for small cell lung cancer with brain metastases
- Development and External Validation of Machine Learning Models for Ionized Calcium Estimation in Hypoalbuminemia
BibTeX
@misc{du2026development,
title = {{Development and External Validation of a Plasma p-tau217-Based Model for MCI-to-Dementia Progression}},
author = {M. Du and I. Roy and B. Chu and S. Tian},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.15.26363045},
url = {https://www.medrxiv.org/content/10.64898/2026.09.15.26363045v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Development and External Validation of a Plasma p-tau217-Based Model for MCI-to-Dementia Progression
AU - M. Du
AU - I. Roy
AU - B. Chu
AU - S. Tian
PY - 2026
DA - 2026/09/15
PB - medRxiv
DO - 10.64898/2026.09.15.26363045
UR - https://www.medrxiv.org/content/10.64898/2026.09.15.26363045v1
AB - --Clinical trajectories after a diagnosis of mild cognitive impairment (MCI) vary widely, so prognostic models must account for both the timing of subsequent diagnoses and unequal follow-up. Using the Alzheimers Disease Neuroimaging Initiative (ADNI), we developed a Cox proportional-hazards model for time from an MCI-aligned plasma index visit to a subsequent dementia diagnosis, using age at study entry and log-transformed plasma p-tau217. Coefficients and baseline survival were estimated in 401 participants with 85 events and then frozen and applied without refitting to an independent cohort from the National Alzheimers Coordinating Center (NACC). NACC p-tau217 measurements were reported on the Quanterix HD-X platform and were mapped to the ADNI development-assay scale using a prespecified transformation derived from paired ADNI measurements. The two-predictor model reached a pooled out-of-fold C-index of 0.775 in ADNI (apparent C-index, 0.778) and 0.652 (95% CI, 0.526-0.765) in 104 NACC participants with 25 incident dementia diagnoses. At two years, observed risk was 0.214 compared with a mean predicted risk of 0.089, an observed-to-expected ratio of 2.40. Neither adding APOE{varepsilon} 4 count, sex, or education nor expanding the model with GFAP, NfL, and the A{beta}42/A{beta}40 ratio materially improved discrimination in ADNI; APOE{varepsilon} 4 also provided no detectable incremental gain in NACC. The model showed moderate discrimination in NACC, although the wide confidence interval includes values near chance and the middle and higher risk tertiles did not clearly separate; C-indices were similar in the bridged primary and direct-scale sensitivity analyses, and mean two-year predicted risk was lower than observed only in the bridged analysis.
ER -